Administration of Mavorixafor, an Orally Available CXCR4 Antagonist, Increases Total White Blood Cell, Neutrophil, Lymphocyte, and Monocyte Counts Across Different Disease States

 

X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.

Continue